GSK-923295: Potent CENP-E Inhibitor for Mitotic Checkpoint Research

Executive Summary: GSK-923295 is a selective, nanomolar-potency inhibitor of the mitotic kinesin motor protein CENP-E, an essential regulator of chromosome congression and metaphase-to-anaphase transition in mitosis (APExBIO). It blocks microtubule-stimulated ATPase activity, arrests cells in mitosis, and mimics morphological outcomes of CENP-E knockdown. In vitro, GSK-923295 inhibits proliferation of diverse tumor cell lines with median GI₅₀ values in the low nanomolar range. In vivo, it induces dose-dependent regression of colon tumor xenografts in mice, accompanied by increased apoptosis. The compound is insoluble in water but highly soluble in DMSO and ethanol, and must be stored at −20°C for stability (APExBIO).

Biological Rationale

Mitosis ensures accurate segregation of duplicated chromosomes to daughter cells. The centromere and associated kinetochore proteins, including centromere-associated protein E (CENP-E), are essential for this process (Walsh et al., 2026). CENP-E is a kinesin-7 family ATPase that mediates chromosome congression by linking spindle microtubules to kinetochores, regulating the mitotic checkpoint signaling pathway and metaphase plate alignment (see here). Disruption of these pathways leads to mitotic errors, aneuploidy, and is implicated in cancer pathogenesis. Specific inhibition of CENP-E allows researchers to dissect the roles of kinetochore-microtubule attachment, checkpoint signaling, and chromosome alignment regulation in cell division (see here for centromere context).

Mechanism of Action of GSK-923295

GSK-923295 is a small-molecule inhibitor that targets the microtubule-stimulated ATPase activity of CENP-E with a reported inhibition constant (K_i) of 3.2 nM (APExBIO). By stabilizing the ATP-bound form of CENP-E, it slows the release of ADP and inorganic phosphate, effectively arresting the protein in a non-motile state on microtubules. This leads to inhibition of chromosome congression, metaphase plate organization, and subsequent metaphase-to-anaphase transition. Morphological outcomes in treated cells mirror those observed with RNAi-mediated depletion of CENP-E, including failure of chromosome alignment and persistent activation of the spindle assembly checkpoint (GSK-923295 mechanism details).

Evidence & Benchmarks

• GSK-923295 inhibits CENP-E ATPase activity at K_i = 3.2 nM under in vitro assay conditions (APExBIO, product page).
• Induces mitotic arrest and chromosome misalignment in cell lines, phenocopying CENP-E RNAi depletion (Walsh et al., 2026).
• Inhibits proliferation across 237 tumor cell lines with an average GI₅₀ of 253 nM and a median GI₅₀ of 32 nM (APExBIO, product page).
• In mouse Colo205 colon xenograft models, intraperitoneal dosing at 125 mg/kg induced dose-dependent tumor regression and increased apoptosis (APExBIO).
• Mitotic errors similar to CENP-E inhibition observed upon CTCF depletion, supporting CENP-E's role in centromere function (Walsh et al., 2026).

This article extends previous guides (e.g., reproducibility and protocol optimization) by providing a direct, evidence-based synthesis of mechanism and benchmarks contextualized by recent centromere research.

Applications, Limits & Misconceptions

GSK-923295 is widely used in cancer research as a reference CENP-E inhibitor for:

• Dissecting mitotic checkpoint signaling pathways.
• Studying chromosome alignment and metaphase plate regulation.
• Screening for synthetic lethality or combination therapies targeting mitotic kinesins (scenario-driven protocols).
• Evaluating cell cycle arrest agents in proliferation and cytotoxicity assays.
• Modeling antitumor activity in colon and other cancer xenografts in vivo.

Compared to earlier reviews (see here), this synthesis clarifies mechanistic details and integrates recent findings on centromere maintenance and mitotic fidelity.

Common Pitfalls or Misconceptions

• GSK-923295 is not a broad-spectrum kinesin inhibitor; it is selective for CENP-E under standard assay conditions.
• It does not induce apoptosis directly; cell death is a downstream result of prolonged mitotic arrest.
• Water solubility is negligible; DMSO or ethanol (with sonication) are required for reliable dissolution.
• Prolonged storage of solutions at room temperature leads to degradation and loss of potency.
• In vivo efficacy and dosing must be carefully optimized; results cannot be directly extrapolated from in vitro IC₅₀/GI₅₀ values.

Workflow Integration & Parameters

• Storage: Store solid GSK-923295 at −20°C; use freshly prepared solutions and minimize freeze/thaw cycles (APExBIO).
• Solubility: ≥29.6 mg/mL in DMSO and ≥14.87 mg/mL in ethanol (with ultrasonic assistance); insoluble in water.
• Working Concentrations: Typical in vitro usage is 10–300 nM for cell-based assays; adjust for cell line sensitivity and endpoint.
• Controls: Include vehicle (DMSO) controls and, where possible, CENP-E knockdown or knockout comparators.
• In Vivo Use: Mouse studies employed 125 mg/kg intraperitoneal dosing, with efficacy in Colo205 xenograft models.
• Safety: For research use only; not for diagnostic or clinical applications.

For detailed experimental scenarios and troubleshooting, refer to the protocol optimization guide.

Conclusion & Outlook

GSK-923295, available from APExBIO, is an established small-molecule CENP-E inhibitor with robust, reproducible activity in cell cycle and cancer research. Its selectivity and potency facilitate precise dissection of mitotic checkpoint signaling and chromosome alignment mechanisms. Integrating GSK-923295 into workflow protocols enables researchers to model mitotic arrest, benchmark antitumor efficacy, and explore the microtubule motor protein pathway in disease. Ongoing studies continue to reveal new facets of centromere and kinetochore regulation, expanding the utility of GSK-923295 in both basic and translational settings.